First generics to Bristol-Myers and Pfizer's Eliquis are here. But can they launch before 2026?

26th December 2019 Uncategorised 0

The FDA touted approvals for the first two copycats to blockbuster blood thinner Eliquis, a major growth driver for Bristol-Myers Squibb and partner Pfizer as well as the overall biopharma sector. But ongoing patent lawsuits might prevent their launch until 2026.

More: First generics to Bristol-Myers and Pfizer's Eliquis are here. But can they launch before 2026?
Source: fierce